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Orthotopic heart transplantation represents
one of the greatest advances of current medical
science, with the potential to restore health to oth-
erwise moribund individuals with end-stage cardi-
ac disease. The transplant procedure, however,
does not represent a “cure”, as patients require life-
long therapy with potent immunosuppressant med-
ications and constant surveillance for life-threaten-
ing complications including allograft rejection and
infection. Following transplantation, patients are
also highly prone to the development of an unusu-
ally aggressive and rapidly progressive form of cor-
onary artery disease often termed cardiac allograft
vasculopathy (CAV), which represents the leading
cause of death among heart transplant patients fol-
lowing the first post-transplant year [1]. CAV ap-
pears to result from a combination of immune-me-
diated and non-immunologic factors that result in
endothelial cell injury, thereby precipitating vascu-
lar smooth muscle cell proliferation and subsequent
intimal thickening. The presence of CAV can be
detected in up to 50% of patients within 5 years of
transplantation, and following the detection of CAV
5 year survival falls to only approximately 20% [2].
The diagnosis of CAV is problematic, as den-
ervation of the transplanted heart typically elimi-
nates the anginal warning system. Because non-
invasive tests have proved unreliable for the detec-
tion of transplant coronary disease, most transplant
centers perform yearly surveillance coronary ang-
iography to screen for and follow the progression
of CAV. Coronary angiography itself tends to un-
derestimate the extent of CAV due to the diffuse
nature of the process. While focal severe coronary
lesions can occur and serve as targets for percuta-
neous coronary intervention (PCI), intravascular
ultrasound imaging has demonstrated that CAV is
typically a diffuse, concentric process that involves
the entirety of the coronary tree from larger prox-
imal vessels to small distal branches [3, 4].
Several institutions have reported their expe-
riences with PCI for CAV, although the ultimate
impact of PCI on survival following heart transplan-
tation remains uncertain [5]. PCI for the treatment
of severe focal lesions is associated with high ini-
tial success rates, but restenosis following either
balloon angioplasty or stenting is much more com-
mon in the post-transplant population than among
non-transplant patients undergoing PCI for athero-
sclerotic coronary disease. Among 65 transplant
patients who underwent PCI at The University of
California at Los Angeles, for example, procedural
success was achieved in 93% of individuals, how-
ever angiographic restenosis rates were 56% fol-
lowing balloon angioplasty and 31% following bare-
metal stenting. Drug-eluting stents were used in
a small number of patients and yielded a restenosis
rate of 19%, however experience and late follow-
up with drug-eluting stents for the treatment of
CAV remains extremely limited [6].
Techniques for the performance of PCI among
patients with CAV have traditionally mirrored those
of PCI for non-transplant patients with atheroscle-
rotic coronary disease. In the current issue of “Car-
diology Journal”, Aqel et al. [7] report on their in-
stitution’s experience using the direct thrombin
inhibitor bivalirudin during PCI for CAV. Rand-
omized multicenter trials have demonstrated that
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the use of bivalirudin during PCI among patients
with stable and unstable coronary syndromes is ef-
ficacious and associated with a lower likelihood of
bleeding complications than the use of combination
therapy with unfractionated heparin and platelet
glycoprotein IIb/IIIa receptor antagonists [8, 9].
This finding has been surprising to some, as long-
standing belief has held that thrombotic complica-
tions resulting from PCI are primarily platelet-me-
diated, and whereas IIb/IIIa antagonists serve as
potent inhibitors of platelet function, bivalirudin acts
principally to inhibit fibrin clot formation and im-
pairs platelet function only indirectly. It is impor-
tant to note that in the Acute Catheterization and
Urgent Intervention Triage Strategy (ACUITY)
study, the largest randomized trial of bivalirudin
versus IIb/IIIa antagonist therapy during PCI, the
efficacy of bivalirudin among patients with acute
coronary syndromes was dependent upon the co-
administration of the oral platelet inhibitor clopidog-
rel prior to PCI. Patients in the trial who received
bivalirudin without clopidogrel pretreatment dem-
onstrated significant 29% increase in ischemic
events compared to patients treated with a IIb/IIIa
antagonist, supporting the need for antiplatelet
therapy during higher risk PCI [9].
While the efficacy of bivalirudin compared to
the IIb/IIIa antagonists in the setting of PCI for
thrombus laden atherosclerotic lesions such as
those found with acute myocardial infarction re-
mains controversial, bivalirudin does seem well
suited for use during PCI of the smooth, hyperplas-
tic lesions associated with CAV. Among the 30 pa-
tients described by Aqel et al. [7] who underwent
a total of 51 PCI procedures using clopidogrel pre-
treatment and intra-procedural bivalirudin, the
30-day incidence of death, MI, or need for target
revascularization was zero, and the incidence of
major bleeding events at 30 days was 3.9%. While
this retrospective, uncontrolled analysis is not ad-
equately powered to provide definitive conclusions,
these low initial complication rates compare favo-
rably with results achieved in larger trials of biva-
lirudin therapy during PCI for atherosclerotic cor-
onary disease, and support further investigation in
the post-transplant population.
In the end, while PCI has the potential to low-
er ischemic burden stemming from severe focal
stenoses arising after heart transplantation, it is
vital to remember that CAV represents a diffuse
relentless disease process. Medical therapies aimed
at prevention of this disseminated process ultimate-
ly represent the best hope for therapy. Several
agents including statins, sirolimus, everolimis, and
diltiazem have been associated with significant re-
ductions in the incidence of CAV, and other agents
will likely emerge as the mechanisms of CAV be-
come better understood. Until such time, specific
investigations to better define the indications and
optimize the safety and efficacy of PCI following
heart transplantation, such as that of Aqel et al. [7],
remain essential.
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